Literature DB >> 6804685

Parathyroid hormone, prolactin, and function of the pituitary-gonadal axis in male patients with acute renal failure.

F Kokot, Z Mleczko, A Pazera.   

Abstract

In 26 patients with acute renal failure (ARF), plasma levels of lutropin (LH), folitropin (FSH), prolactin, testosterone, estradiol, and parathyroid hormone (PTH) were studied at the anuric/oliguric (AOP) and polyuric phase. Significantly elevated levels of LH, FSH, and prolactin were found during the AOP. Administration of luliberin (LH-RH) was followed by normal or even excessive and prolonged increase of plasma LH and FSH levels during the AOP. Basal plasma testosterone was significantly depressed, but estradiol was moderately elevated at the AOP. Administration of LH-RH did not influence significantly either testosterone or estradiol levels in blood plasma. A negative correlation was found between plasma prolactin and testosterone, and a positive one was found between prolactin and estradiol at the AOP of ARF. In contrast to chronic renal failure, PTH was not significantly correlated with either plasma testosterone or prolactin. We conclude that the hyporesponsiveness of Leydig's cell to the LH signal is the cause of depressed testosterone biosynthesis. It seems probable that prolactin, but not PTH, is involved in the pathogenesis of testicular dysfunction in patients with ARF.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804685     DOI: 10.1038/ki.1982.12

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

1.  Prolactin secretion in kidney transplant patients.

Authors:  W Grzeszczak; F Kokot; A Wiecek; E Zukowska-Szczechowska
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

2.  Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment.

Authors:  D Verbeelen; L Vanhaelst; A C Van Steirteghem; J Sennesael
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.